GPT and hypophosphatemia: In the study by Levine et al. (2019), detailed reports of adverse events were provided, with 12 cases in the PEN+CDED group (including transient ALT elevation, viral infection, hospitalization-fever and gastroenteritis, flare, hospitalization flare, elevated amylase/lipase, upper respiratory infection, hypophosphatemia, herpes zoster, acute gastroenteritis, drug-induced emesis, hematemesis) and 13 cases in the EEN group (including transient ALT elevation, exacerbation, Nausea, flare, hospitalization flare, diarrhea, cough, skin abscess, headache).